Progress: Procedure completed
Role | Committee | Rapporteur | Shadows |
---|---|---|---|
Lead | ENVI | COLIN-OESTERLÉ Nathalie ( EPP) | GONZÁLEZ CASARES Nicolás ( S&D), GLÜCK Andreas ( Renew), METZ Tilly ( Verts/ALE), KOPCIŃSKA Joanna ( ECR), KONEČNÁ Kateřina ( GUE/NGL) |
Lead committee dossier:
Legal Basis:
TFEU 168-p4
Legal Basis:
TFEU 168-p4Subjects
Events
The European Parliament adopted by 461 votes to 56, with 66 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council on standards of quality and safety for substances of human origin intended for human application and repealing Directives 2002/98/EC and 2004/23/EC.
The European Parliament’s position adopted at first reading under the ordinary legislative procedure amends the proposal as follows:
Subject matter and scope
This Regulation establishes measures that set high standards of quality and safety for all substances of human origin (SoHO) intended for human application and for activities related to those substances. It ensures a high level of human health protection, in particular for SoHO donors, SoHO recipients and offspring from medically assisted reproduction, including by strengthening the continuity of supply of critical SoHO.
The Regulation applies to: (i) SoHO intended for human application; (ii) SoHO donors, SoHO recipients and offspring from medically assisted reproduction; (iii) SoHO activities that have a direct impact on the quality, safety or effectiveness of SoHO.
It should not apply to: (i) organs intended for transplantation; (ii) breast milk when used exclusively for feeding one’s own child, without any processing carried out by a SoHO entity.
Competent authorities
Member States should designate the SoHO competent authorities to which they entrust responsibility for SoHO monitoring activities. The designated SoHO Competent Authorities should be independent from any SoHO entity. Member States should ensure that the SoHO competent authorities have sufficient human and financial resources, operational capacity and expertise, including technical expertise, to achieve the objectives of this Regulation.
When carrying out their tasks and exercising their powers, the SoHO competent authorities should act independently and impartially , in the public interest and free from any external influence, which could constitute political influence or interference by industry. They should carry out the SoHO supervisory activities for which they have been charged in a transparent manner and should make available and clear to the public any enforceable decision and the reasons for that decision, in cases where an SoHO entity fails to comply with this Regulation.
SoHO donor and recipient protection
SoHO entities should : (i) ensure respect for the dignity and integrity of SoHO donors ; (ii) ensure high levels of safety and protect the health of living SoHO donors from risks related to the SoHO donation, by identifying and minimising such risks before, during and after the SoHO collection.
Where SoHO is collected from a SoHO donor, SoHO entities should:
- provide SoHO donors or, where applicable, any person giving consent on their behalf with: (i) information in a manner appropriate to their ability to understand; (ii) the contact details of the SoHO entity responsible for the collection, from which they may, where appropriate, request further information;
- safeguard the living SoHO donor's rights to physical and mental integrity, non-discrimination, privacy and the protection of personal data;
- verify the eligibility of the living SoHO donor on the basis of an assessment of his or her state of health aimed at identifying, with a view to minimising, the risk that SoHO donation could represent for his or her health;
- check that living donors do not donate more frequently than is indicated as safe;
- draw up a plan for monitoring the donor's health after SoHO donation in cases where the donation of a substance of human origin involves a significant risk for a living donor.
SoHO entities that collect SoHO from living SoHO donors should register such SoHO donors in a SoHO entity registry or, where available, in national or recognised international registries, to verify donation frequency.
Where Member States allow for the compensation of living SoHO donors , in accordance with the principle of voluntary and unpaid donation and based on transparent criteria, including through fixed allowances, or through non-financial forms of compensation, the conditions for such compensation should be established in national legislation, including by setting an upper limit for compensation that should endeavour to guarantee financial neutrality. Any promotion and publicity activities in support of the donation of SoHO should not refer to compensation.
SoHO entities should provide living SoHO donors or, where applicable, any person giving consent on behalf of a SoHO donor, with all appropriate information relating to the SoHO donation process. This information should cover the purpose and nature of the SoHO donation, the intended use of the donated SoHO, specifically covering proven benefits for the future SoHO recipients and any possible research or commercial uses of SoHO, and the obligation for consent, in accordance with national legislation, in order for SoHO collection to be carried out.
SoHO entities should protect the health of SoHO recipients and offspring from medically assisted reproduction from risks posed by SoHO and their human application, within the scope of their competences. They should do so by identifying and minimising or eliminating those risks. Procedures that achieve high levels of quality and safety of SoHO should be established to ensure that benefits for SoHO recipients and offspring from medically assisted reproduction outweigh residual risks.
Critical SoHO supply sufficiency
Member States should, within their territories and in collaboration with SoHO national authorities, SoHO competent authorities and SoHO entities, each within their respective competence, consider all reasonable efforts for achieving a sufficient, adequate and resilient supply of critical SoHO with a view to appropriately meet recipients’ needs, and to contribute to European self-sufficiency .
Member States, in collaboration with SoHO national authorities, should draw up national SoHO emergency plans setting out measures to be applied without undue delay when the demand or the supply situation for critical SoHO present, or is likely to present, a serious risk to human health.
Critical SoHO entities should, without undue delay, send a SoHO supply alert to their SoHO competent authorities in the event of significant shortages of supply of critical SoHO, indicating the underlying reasons, the expected impact on recipients and any mitigating actions taken.
EU SoHO Platform
The Commission should establish, manage and maintain a digital platform to facilitate efficient and effective exchange of information concerning SoHO activities in the Union.
The European Parliament adopted by 483 votes to 82, with 59 abstentions, amendments to the proposal for a regulation of the European Parliament and of the Council on standards of quality and safety for substances of human origin intended for human application and repealing Directives 2002/98/EC and 2004/23/EC.
The matter was referred back to the committee responsible for inter-institutional negotiations.
Scope
The amended text establishes provisions on:
- exchange of information on availability and stocks of SoHOs, and promotion of actions relating to the security of SoHO supply;
- coordination between competent authorities and the Commission and Union agencies in the event of SoHO related health emergencies.
Members stipulated that this Regulation should not apply to breast milk that is expressed by a mother solely for the purpose of feeding her own child.
Voluntary and unpaid donation
Parliament stated that ‘ SoHO donation ’ means a process by which a person voluntarily and altruistically gives SoHOs from their own body to people in need, or authorises their use after their death. This includes the necessary medical formalities, examination and treatments and monitoring of the SoHO donor, irrespective of whether that donation is successful or not; it also includes when consent is given by an authorised person in accordance with national legislation.
Members stressed the fact that Member States may allow for the compensation or reimbursement from the SoHO entities to living SoHO donors for losses or expenses related to their participation in donations, in accordance with the principle of voluntary and unpaid donation, and for example taking the form of compensatory leave, tax reductions or flat rate allowances set at national level. Compensation or reimbursement should not serve as an incentive for donations or engender financial competition, including cross-border competition, between institutions and entities that are seeking donors. It should not lead to exploitation of vulnerable persons in society . Member States should regulate the advertising of the collection of SoHOs. Any advertising of SoHO donations linked to a financial reward should be prohibited. Recruitment campaigns and advertisements shall not refer to any compensation.
SoHO entities should provide the information in an accurate and clear manner, using terms that are easily understood by the prospective donors or the persons to consent or authorise the donation, and ensure that the consent given is informed consent .
Protection of recipients
SoHO entities should not discriminate against SoHO recipients on any of the grounds listed in Article 21 of the Charter of Fundamental Rights of the European Union, unless it is necessary to protect the health of the SoHO recipient or of the SoHO donor. Such discriminatory action shall be based on scientific evidence.
Where possible, SoHO entities should use technologies to reduce clinical risks for SoHO recipients and offspring from medically assisted reproduction, and to improve the quality of SoHOs.
Members introduced the possibility of a derogation from the obligation to authorise preparations based on substances of human origin in emergency situations or in situations where there is no therapeutic alternative.
Establishment of national emergency plans
In order to ensure EU self-sufficiency in SoHO supply, Member States should draw up national plans to strive for sufficiency of supply of critical SoHOs and contribute to European autonomy in the context of a resilient supply chain.
The national plans should in particular include measures to ensure that the donor base is resilient, actions to make a more efficient use of SoHOs, monitoring of trends in the supply of critical SoHOs as well as measures for cases where national SoHO stocks exceed the national demand and SoHOs are exported to other countries with SoHO shortages.
Members also called on the EU to establish a digital communication channel as part of these national plans, enabling information on the availability of substances of human origin on national territory to be exchanged quickly and efficiently.
EU strategy
By two years after the date of entry into force of this regulation, the Commission should publish a strategy for the promotion of European SoHO supply autonomy . That strategy should set out a roadmap with ambitious targets for each critical SoHO, laid down by the Commission in coordination with national competent authorities, the SCB, the ECDC, the European Parliament, scientists from professional associations and patient associations, as well as with all other relevant stakeholders.
The strategy should set out a roadmap with ambitious targets for each critical SoHO. It should promote actions to:
- support and coordinate communication campaigns at European and national level on the various types of SoHO donations that are available;
- support, through relevant programmes, the training of healthcare workers in hospital and healthcare facilities, to raise awareness concerning SoHO donations;
- coordinate the exchange of best practices linked to optimisation of the use of critical SoHOs.
The strategy should include actions to establish a Union list of critical SoHOs.
SoHO platform
To limit administrative burden on competent authorities and the Commission, the latter should establish an online platform (EU SoHO Platform) to facilitate timely submission of data and reports, to make it possible to share the elements used to determine the regulatory status of a substance, to improve the transparency of national reporting and supervisory activities and ensure better communication, collaboration and coordination in relation to, and exchange of, SoHOs between Member States.
The EU SoHO Platform should also be the main intermediary for reporting SoHO shortages, for cross-border requests for SoHOs and for import and export of SoHOs.
The Committee on the Environment, Public Health and Food Safety adopted the report by Nathalie COLIN-OESTERLÉ (EPP, FR) on the proposal for a regulation of the European Parliament and of the Council on standards of quality and safety for substances of human origin intended for human application and repealing Directives 2002/98/EC and 2004/23/EC.
The committee responsible recommended that the European Parliament's position adopted at first reading under the ordinary legislative procedure should amend the proposal as follows:
Scope
The amended text establishes provisions on:
- exchange of information on availability and stocks of SoHOs, and promotion of actions relating to the security of SoHO supply;
- coordination between competent authorities and the Commission and Union agencies in the event of SoHO related health emergencies.
It should be noted that Members stipulated that this Regulation should not apply to breast milk that is expressed by a mother solely for the purpose of feeding her own child.
More stringent measures
Members stressed that the protection of donors and recipients should be ensured through the highest quality and safety standards. They suggested that the principle of voluntary and unpaid donation should be harmonised, in particular with a view to stopping differences in national rules from encouraging citizens to donate in other countries than their own for financial reasons.
Members insisted that EU countries should allow for compensation or reimbursement for losses or expenses, related to their participation in donations, to living donors. This could be facilitated through for example, compensatory leave, tax reductions or flat rate allowances set at the national level. They stressed that compensation should not be used as an incentive to recruit donors, nor lead to the exploitation of vulnerable people. The report also called on the EU to enforce strict rules on advertising around SoHO donations, which should prohibit any references to financial rewards. Moreover, recruitment campaigns and advertisements should not refer to any compensation.
The report also called for greater efforts to harmonise donation frequency rules between the Member States by giving the European Commission the power to adopt delegated acts on this specific matter.
Safeguarding supply
To ensure the autonomy of the EU’s supply of these substances, EU countries should establish national emergency and continuity of supply plans , which should include measures to ensure a resilient donor base, monitoring of the supply of critical SoHOs and proposals to improve cooperation between countries with excess stocks and those experiencing shortages. Members also called for the EU to establish a digital communication channel as part of these national plans, to store and analyse information on SoHOs availability, fluctuations and potential shortages.
EU strategy
Members called for the development of a strategy for the promotion of European SoHO supply autonomy. The strategy should set out a roadmap with ambitious targets for each critical SoHO. It should promote actions to:
- support and coordinate communication campaigns at European and national level on the various types of SoHO donations that are available;
- support, through relevant programmes, the training of healthcare workers in hospital and healthcare facilities, to raise awareness concerning SoHO donations;
- coordinate the exchange of best practices linked to optimisation of the use of critical SoHOs.
The strategy should include actions to establish a Union list of critical SoHOs .
SoHO platform
To limit administrative burden on competent authorities and the Commission, the latter should establish an online platform (EU SoHO Platform) to facilitate timely submission of data and reports, to make it possible to share the elements used to determine the regulatory status of a substance, to improve the transparency of national reporting and supervisory activities and ensure better communication, collaboration and coordination in relation to, and exchange of, SoHOs between Member States.
In order to prevent supply tensions and to ensure donor and recipient security, the Commission should ensure that the EU SoHO Platform is interoperable with the other existing Union platforms, in particular the EMA’s European Shortages Monitoring Platform. The EU SoHO Platform should also be the main intermediary for reporting SoHO shortages, for cross-border requests for SoHOs and for import and export of SoHOs.
PURPOSE: to ensure a high level of health protection for EU citizens and ensure access to safe and effective substances of human origin (blood, tissue and cells) (SoHOs).
PROPOSED ACT: Regulation of the European Parliament and of the Council.
ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.
BACKGROUND: every year, EU patients are treated with 25 million blood transfusions (during emergency surgery, cancer or other care), a million cycles of medically assisted reproduction, over 35 000 transplants of stem cells (mainly for blood cancers) and hundreds of thousands of replacement tissues (e.g., for orthopaedic, skin, cardiac or eye problems).
The EU framework for safety and quality of substances of human origin (SoHOs) has currently three main Directives, respectively for Blood, Tissues and Cells, and Organs , together with implementing legislation.
Although these Directives have harmonised to a certain degree the rules of Member States in the area of safety and quality of blood, tissues and cells, they include a significant number of options and possibilities for Member States to implement the rules they laid down. This results in divergences between national rules , which can create obstacles to cross-border sharing of these substances.
A fundamental revision of those Directives is needed for a robust, transparent, up-to-date and sustainable regulatory framework for these substances, which achieves safety and quality for all parties involved, enhances legal certainty and supports continuous supply, whilst facilitating innovation for the benefit of public health. In addition, the proposal aims to tackle concerns regarding the sufficiency of supply highlighted by the COVID-19 pandemic.
This initiative is part of the EU’s ambition to build a stronger European Health Union.
CONTENT: the proposed Regulation aims to establish measures setting high standards of quality and safety for all substances of human origin intended for human applications and for activities related to these substances, in order to ensure a high level of human health protection, in particular for donors of substances of human origin, recipients of substances of human origin and offspring of medically assisted reproduction.
All substances of human origin would be covered, with the exception of solid organs. Human breast milk is one of the new substances covered by the proposal.
More specifically, the proposal provides for measures to:
- ensure safety and quality for patients receiving SoHO therapies and fully protect them from avoidable risks related to substances of human origin;
- ensure safety and quality for donors of substances of human origin and for children born from donated eggs, sperm or embryos;
- empower the EU and its Member States to better prevent and combat future pandemics (surveillance, data analysis, risk assessment, early warning and rapid response);
- facilitate the development of innovative, safe and effective SoHO therapies ;
- improve the resilience of European health systems (sufficient supply of human-derived substances) by mitigating the risk of shortages.
Specifically, the proposal:
- improves the protection of patients treated with SoHO (recipients) and offspring from medically assisted reproduction, with standards, and how to implement these standards concerning recipient and offspring protection;
- contains provisions on the competent authorities for substances of human origin, which are responsible for the supervisory activities;
- covers all activities that competent authorities undertake in relation to SoHO entities or registration procedures, with the obligation to maintain a register of SoHO entities and to establish a procedure for their registration ;
- describes all general obligations on SoHO entities, namely their registration, the nomination of a Responsible Person if they release substances of human origin for clinical use, as well as obligations regarding the export of SoHOs;
- requires blood and tissue establishments to meet safety and quality standards by following guidelines developed and updated by designated expert bodies such as the European Centre for Disease Prevention and Control (ECDC) and the European Directorate for the Quality of Medicines and Health Care (Council of Europe);
- lays down provisions to ensure the continuity of supply of SoHOs . It covers the obligation for Member States to have national SoHO emergency plans (for SoHOs that are critically important for patients) and the responsibilities of competent authorities and entities regarding supply alerts for critical SoHOs.
A SoHO Coordination Board (SCB) would be established with and for the Member States to support a common implementation of the new Regulation.
The creation of the EU SoHO Platform , to gather all required information, streamline reporting and increase visibility to citizens will give a new impetus to digitalisation.
BUDGETARY IMPLICATIONS: the financial impact of the proposal is estimated at EUR 55.411 million in commitment appropriations for the period 2024-2027. The appropriations will be reallocated within the financial envelope of the EU Health Programme in the Multiannual Financial Framework (MFF) 2021-2027.
Documents
- Draft final act: 00008/2024/LEX
- Decision by Parliament, 1st reading: T9-0353/2024
- Approval in committee of the text agreed at 1st reading interinstitutional negotiations: PE758.999
- Coreper letter confirming interinstitutional agreement: GEDA/A/(2024)000898
- Text agreed during interinstitutional negotiations: PE758.999
- Results of vote in Parliament: Results of vote in Parliament
- Decision by Parliament, 1st reading: T9-0299/2023
- Committee report tabled for plenary, 1st reading: A9-0250/2023
- Amendments tabled in committee: PE740.835
- Amendments tabled in committee: PE745.276
- Amendments tabled in committee: PE745.277
- Committee draft report: PE738.661
- Contribution: COM(2022)0338
- Economic and Social Committee: opinion, report: CES4815/2022
- Contribution: COM(2022)0338
- Contribution: COM(2022)0338
- Document attached to the procedure: OJ C 450 28.11.2022, p. 0007
- Document attached to the procedure: N9-0084/2022
- Document attached to the procedure: EUR-Lex
- Document attached to the procedure: SEC(2022)0304
- Document attached to the procedure: EUR-Lex
- Document attached to the procedure: SWD(2022)0189
- Document attached to the procedure: SWD(2022)0190
- Document attached to the procedure: EUR-Lex
- Document attached to the procedure: SWD(2022)0191
- Legislative proposal published: COM(2022)0338
- Legislative proposal published: EUR-Lex
- Document attached to the procedure: EUR-Lex SEC(2022)0304
- Document attached to the procedure: EUR-Lex SWD(2022)0189
- Document attached to the procedure: SWD(2022)0190
- Document attached to the procedure: EUR-Lex SWD(2022)0191
- Document attached to the procedure: OJ C 450 28.11.2022, p. 0007 N9-0084/2022
- Economic and Social Committee: opinion, report: CES4815/2022
- Committee draft report: PE738.661
- Amendments tabled in committee: PE740.835
- Amendments tabled in committee: PE745.276
- Amendments tabled in committee: PE745.277
- Coreper letter confirming interinstitutional agreement: GEDA/A/(2024)000898
- Text agreed during interinstitutional negotiations: PE758.999
- Draft final act: 00008/2024/LEX
- Contribution: COM(2022)0338
- Contribution: COM(2022)0338
- Contribution: COM(2022)0338
Activities
- Nathalie COLIN-OESTERLÉ
Plenary Speeches (3)
- 2023/09/12 Standards of quality and safety for substances of human origin intended for human application (A9-0250/2023 - Nathalie Colin-Oesterlé) (vote)
- 2023/09/12 Standards of quality and safety for substances of human origin intended for human application (A9-0250/2023 - Nathalie Colin-Oesterlé) (vote)
- 2024/04/24 Standards of quality and safety for substances of human origin intended for human application (A9-0250/2023 - Nathalie Colin-Oesterlé) (vote)
Votes
Normes de qualité et de sécurité des substances d’origine humaine destinées à une application humaine - A9-0250/2023 - Nathalie Colin-Oesterlé - Amendements de la commission compétente - vote en bloc - Am 59 #
A9-0250/2023 - Nathalie Colin-Oesterlé - Amendements de la commission compétente - vote en bloc - Am 85 #
A9-0250/2023 - Nathalie Colin-Oesterlé - Proposition de la Commission #
A9-0250/2023 – Nathalie Colin-Oesterlé – Provisional agreement – Am 244 #
Amendments | Dossier |
757 |
2022/0216(COD)
2023/03/14
ENVI
757 amendments...
Amendment 118 #
Proposal for a regulation Recital 1 a (new) (1a) In accordance with Article 1 of the Charter of Fundamental Rights of the European Union, which states that ‘human dignity is inviolable. It must be respected and protected,' and Article 3 of same, the quality and safety standards of SoHOs must respect the physical and mental integrity of the persons concerned, ensure SoHOs are donated with the free and informed consent of those persons and prohibit eugenic principles, financial gain from the human body or its parts and cloning,
Amendment 119 #
Proposal for a regulation Recital 1 a (new) (1a) In accordance with Article 168(1), first subparagraph, of the Treaty on the Functioning of the European Union (TFEU) and Article 35 of the Charter of Fundamental Rights of the European Union, a high level of human health protection is to be ensured in the definition and implementation of all Union policies and activities.
Amendment 120 #
Proposal for a regulation Recital 1 b (new) (1b) The scope of this regulation goes beyond the subject matters addressed in previous directives. Reproductive techniques and the use of SoHos as starting materials for medicinal products raise very complex questions that are tackled in a fragmented manner by the Member States in legal and ethical contexts. Both matters require ad hoc legislation that responds effectively to their specific nature.
Amendment 121 #
Proposal for a regulation Recital 1 c (new) (1c) Reproductive techniques, tissue banks and pharmaceutical industries have specific characteristics that make it difficult to establish a common standard to provide the quality, safety and efficacy needed to ensure good practice in these areas.
Amendment 122 #
Proposal for a regulation Recital 1 d (new) (1d) The development of legislation in the areas of reproductive techniques, tissue banks and pharmaceutical industries must reflect the importance of donation and the need for enhanced traceability because of their implications for health-related information and the existence of third parties.
Amendment 123 #
Proposal for a regulation Recital 3 (3) As regards Article 168(4), point (a), TFEU, standards for the safety and quality of organs and SoHOs, blood and blood derivatives should ensure a high level of human health protection. Therefore, this Regulation aims at setting high standards by ensuring, amongst others, the protection of SoHO donors, taking into consideration their fundamental role in the provision of SoHOs and for recipients, as well as measures to monitor and support the sufficiency of the supply of SoHOs that are critical for the health of patients. In accordance with Article 3 of the Charter of Fundamental Rights of the European Union, these safety standards are based on the fundamental principle that the human body cannot be commercialised, which holds that no SoHO may be sold, as well as on the principle of the unavailability of the human body and the principle that the human body or parts thereof cannot be used for financial gain.
Amendment 124 #
Proposal for a regulation Recital 3 (3) As regards Article 168(4), point (a), TFEU, standards for the safety and quality of organs and SoHOs, blood and blood derivatives should ensure a high level of human health protection. Therefore, this Regulation aims at setting high safety standards by ensuring, amongst others, the protection of SoHO donors, taking into consideration their fundamental role in the provision of SoHOs and for recipients, as well as measures to monitor and support the sufficiency of the supply of SoHOs that are critical for the health of patients.
Amendment 125 #
Proposal for a regulation Recital 4 (4) Directives 2002/98/EC16and 2004/23/EC17of the European Parliament and of the Council constitute the Union’s regulatory framework for blood and for tissues and cells, respectively. Although these Directives have harmonised to a certain degree the rules of Member States in the area of safety and quality of blood, tissues and cells, they include a significant number of options and possibilities for Member States to implement the rules they laid down. This results in divergences between national rules, which can create obstacles to cross-border sharing of these
Amendment 126 #
Proposal for a regulation Recital 4 (4) Directives 2002/98/EC16and 2004/23/EC17of the European Parliament and of the Council constitute the Union’s regulatory framework for blood and for tissues and cells, respectively. Although these Directives have harmonised to a
Amendment 127 #
Proposal for a regulation Recital 5 (5) Directives 2002/98/EC and 2004/23/EC are highly interconnected and contain very similar provisions for oversight and equivalent principles for safety and quality in the two sectors they regulate. In addition, many authorities and operators work across these sectors. As this Regulation aims to define high level principles that will be common to both the blood and of tissues and cells sectors, it would be appropriate that it replaces these Directives and merges the revised provisions into one legal act, with respect for the special characteristics of each of the substances recognised in the technical guidelines set out in this Regulation.
Amendment 128 #
Proposal for a regulation Recital 5 (5) Directives 2002/98/EC and 2004/23/EC are highly interconnected and contain very similar provisions for oversight and equivalent principles for safety and quality in the two sectors they regulate. In addition, many authorities and operators work across these sectors. As this Regulation aims to define high level principles that will be common to both the blood and of tissues and cells sectors, it would be appropriate that it replaces these Directives and merges the revised provisions into one legal act, taking into consideration the special characteristics of each type of substance.
Amendment 129 #
Proposal for a regulation Recital 6 (6) This Regulation should apply to blood and blood components, as regulated by Directive 2002/98/EC, as well as to tissues and cells, including haematopoietic peripheral blood, umbilical-cord blood and bone-marrow stem cells, reproductive cells and tissues, foetal tissues and cells
Amendment 130 #
Proposal for a regulation Recital 7 (7) Solid organs are excluded from the definition of SoHOs for the purposes of
Amendment 131 #
Proposal for a regulation Recital 8 a (new) (8a) The EU shall further the development of a European SoHO sovereignty with a view to preventing dependency on third countries with regard to sectors and products of strategical importance for the EU.
Amendment 132 #
Proposal for a regulation Recital 8 b (new) (8b) Every step must be taken to prevent the development or the EU playing a role in the development of a paid cell and tissue donation industry.
Amendment 133 #
Proposal for a regulation Recital 9 (9) All SoHOs that are intended to be applied to humans fall within the scope of this Regulation. SoHOs can be prepared and stored in a variety of ways, becoming SoHO preparations, which can be applied to recipients. In these circumstances, this Regulation should apply to all activities from donor recruitment to human application and outcome monitoring. SoHOs or SoHO preparations can also be used to manufacture products regulated by other Union legislation, or as the starting and raw material thereof, in particular on medical devices, regulated by Regulation (EU) 2017/745 of the European Parliament and of the Council19, on medicinal products, regulated by Directive 2001/83/EC of the European Parliament and of the Council20and by Regulation (EC) No 726/2004 of the European
Amendment 134 #
Proposal for a regulation Recital 9 (9) All SoHOs that are intended to be applied to humans fall within the scope of this Regulation. SoHOs can be prepared and stored in a variety of ways in order to preserve all properties that ensure their compatibility with recipients, becoming SoHO preparations, which can be applied to recipients. In these circumstances, this Regulation should apply to all activities from donor recruitment to human application and outcome monitoring. SoHOs or SoHO preparations can also be used to manufacture products regulated by other Union legislation, or as the starting and raw material thereof, in particular on medical devices, regulated by Regulation (EU) 2017/745 of the European Parliament and of the Council19, on medicinal products, regulated by Directive 2001/83/EC of the European Parliament and of the Council20and by Regulation (EC) No 726/2004 of the European Parliament and of the Council21, including on advanced therapy medicinal products, regulated by Regulation (EC) No 1394/2007 of the European Parliament and of the Council22, or on food, regulated by Regulation (EC) No 1925/2006 of the European Parliament and of the Council23. The criteria that define when SoHOs or SOHO preparations become products
Amendment 135 #
Proposal for a regulation Recital 9 (9) All SoHOs that are intended to be applied to humans fall within the scope of this Regulation. SoHOs can be prepared and stored in a variety of ways, becoming SoHO preparations, which can be applied to recipients. In these circumstances, this Regulation should apply to all activities from donor recruitment to human application and outcome monitoring. SoHOs or SoHO preparations can also be used to manufacture products regulated by other Union legislation, or as the starting and raw material thereof, in particular on medical devices, regulated by Regulation (EU) 2017/745 of the European Parliament and of the Council19, on medicinal products, regulated by Directive 2001/83/EC of the European Parliament and of the Council20and by Regulation (EC) No 726/2004 of the European Parliament and of the Council21, including on advanced therapy medicinal products, regulated by Regulation (EC) No 1394/2007 of the European Parliament and of the Council22, or on food, regulated by Regulation (EC) No 1925/2006 of the European Parliament and of the Council23. When SoHOs qualify or are used in medicinal products regulated by EU legislations mentioned above, only the provisions of this Regulation related to donor protection should be applicable.The criteria that define when SoHOs or SOHO preparations
Amendment 136 #
Proposal for a regulation Recital 10 (10) When SoHOs are used in the autologous setting without any manipulation, processing or storage, the
Amendment 137 #
Proposal for a regulation Recital 10 (10) When SoHOs are used in the autologous setting without any manipulation, processing or storage, the application of this Regulation would not be proportionate to the limited quality and safety risks arising in such a setting. Furthermore, if minimal processing is needed to restore applicability during a surgical procedure or the manipulation is done within a closed system, the Regulation should not apply as well. When autologous SoHOs are collected and
Amendment 138 #
Proposal for a regulation Recital 10 Amendment 139 #
Proposal for a regulation Recital 10 (10) When SoHOs are used in the autologous setting without any manipulation, processing or storage, the application of this Regulation would not be proportionate to the limited quality and safety risks arising in such a setting. When autologous SoHOs are collected and processed before being re-used in the same person, risks appear that should be mitigated. Thus, there needs to be an assessment and authorisation of the processes applied to ensure that they are demonstrated to be safe and effective for the recipient. When autologous SoHOs are collected to be processed and also stored, risks of cross-contamination or contamination of caregivers, friends or family, loss of traceability or damage to the biological properties inherent to the substance, and necessary for efficacy in the recipient, also appear. Thus, the requirements for SoHO establishment authorisation should apply.
Amendment 140 #
Proposal for a regulation Recital 11 (11) When SoHOs are used to manufacture products regulated by other Union legislation, or as the starting and raw material thereof, in order to ensure a high level of protection and contribute to legal clarity and certainty, this Regulation should apply to the extent that the activities to which they are subjected are not regulated by the other Union legislative framework. Without prejudice to other Union legislation, and in particular to Directive 2001/83/EC, Regulations (EC) No 726/2004, (EC) No 1925/2006, (EC) No 1394/2007
Amendment 141 #
Proposal for a regulation Recital 11 (11) When SoHOs are used to manufacture products regulated by other Union legislation, or as the starting and raw material thereof, in order to ensure a high level of protection and contribute to legal clarity and certainty, this Regulation should apply to the extent that the activities to which they are subjected are not regulated by the other Union legislative framework. Without prejudice to other Union legislation, and in particular to Directive 2001/83/EC, Regulations (EC) No 726/2004, (EC) No 1925/2006, (EC) No 1394/2007 and (EU) 2017/745, this Regulation should at least apply to the recruitment and selection of donors, donation, collection and donor testing as well as to release, distribution, dispensing, import and export when those activities concern SoHOs up to the point of their transfer to operators regulated by other Union legislation. This means that close interaction between this regulatory framework and other related frameworks is essential to ensure interplay and coherence between relevant legal frameworks, without gaps or overlaps.
Amendment 142 #
Proposal for a regulation Recital 11 (11) When SoHOs are used to manufacture products regulated by other Union legislation, or as the starting and raw material thereof, in order to ensure a high level of protection and contribute to legal clarity and certainty, this Regulation should apply to the extent that the activities to which they are subjected are not regulated by the other Union legislative framework. Without prejudice to other Union legislation, and in particular to Directive 2001/83/EC, Regulations (EC) No 726/2004, (EC) No 1925/2006, (EC) No 1394/2007 and (EU) 2017/745, this Regulation should at least apply to the recruitment and selection of donors, donation, collection and donor testing as well as to release, distribution, issuing, import and export when those activities concern SoHOs up to the point of their transfer to operators regulated by other Union legislation. This means that close interaction between this regulatory framework and other related frameworks is essential to ensure interplay and coherence between relevant legal frameworks, without gaps or overlaps.
Amendment 143 #
Proposal for a regulation Recital 12 (12) SoHOs can also be combined with other regulated products before human application. In these circumstances, close interaction between this regulatory framework and other related frameworks is
Amendment 144 #
Proposal for a regulation Recital 12 (12) SoHOs can also be combined with other regulated products before, exclusively, human application. In these circumstances, close interaction between this regulatory framework and other related frameworks is also necessary to ensure a high level of human health protection for all cases where these substances are used.
Amendment 145 #
Proposal for a regulation Recital 12 a (new) (12a) The scope of this regulation shall have no effect on national assisted reproduction legislation. Sexual and reproductive rights are a national competence.
Amendment 146 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs, resulting from their human origin, and the increasing demands for these substances for human application or for the manufacture of products regulated by other Union legislation, or as the starting and raw material thereof, it is necessary to ensure a high level of health protection for donors as well as for recipients. SoHOs should be obtained from individuals whose health status is such that no detrimental effects will ensue as a result of the donation. This Regulation should therefore include principles and technical rules to monitor and protect donors. As different types of donation imply different risks for donors, with varying levels of significance, the monitoring of donor health should be proportionate to those levels of risk.
Amendment 147 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs,
Amendment 148 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs, resulting from their human origin, and the increasing demands for these substances for human application or for the manufacture of products regulated by other Union legislation, or as the starting and raw material thereof, it is necessary to ensure a high level of health protection for donors as well as for recipients. SoHOs
Amendment 149 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs, resulting from their human origin, and the increasing demands for these substances for human application or for the manufacture of products regulated by other Union legislation, or as the starting and raw material thereof, it is necessary to ensure a high level of health protection for
Amendment 150 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs, resulting from their human origin, and the increasing demands for these substances for human application or for the manufacture of products regulated by other Union legislation, or as the starting and raw material thereof, it is necessary to
Amendment 151 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs, resulting from their human origin, and the increasing demands for these substances for human application or for the manufacture of products regulated by other Union legislation, or as the starting and raw material thereof, it is necessary to ensure a high level of health protection for donors as well as for recipients. SoHOs should be obtained from individuals whose health status is such that no detrimental effects will ensue as a result of the donation. This Regulation should therefore
Amendment 152 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs, resulting from their human origin, and the increasing demands for these substances for human application or for the manufacture of products regulated by other Union legislation, or as the starting and raw material thereof, it is necessary to ensure a high level of health protection when handling these products and hence for donors as well as for recipients. SoHOs should be obtained from individuals whose health status is such that no detrimental effects will ensue as a result of the donation. This Regulation should therefore include principles and technical rules to monitor and protect donors from undesirable short-term and long-term side-effects. As different types of donation imply different risks for
Amendment 153 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs, resulting from their human origin, and the increasing demands for these substances for human application or for the manufacture of products regulated by other Union legislation, or as the starting and raw material thereof, it is necessary to ensure a high level of health protection for donors as well as for recipients. SoHOs should be obtained from individuals whose health status is such that no detrimental effects will ensue as a result of the donation. This Regulation should therefore include principles and technical rules to monitor and protect donors. As different types of donation imply different risks for donors, with varying levels of significance, the monitoring of donor health should be proportionate to those levels of risk. This is particularly important when donation involves some risk to the donor’s health due to a need for pre-treatment with
Amendment 154 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs, resulting from their human origin, and the increasing demands for these substances for human application or for the manufacture of products regulated by other Union legislation, or as the starting and raw material thereof, it is necessary to ensure a high level of health protection for donors as well as for recipients. SoHOs should be obtained from individuals whose health status is such that no detrimental effects will ensue as a result of the donation. This Regulation should therefore include principles and technical rules to monitor and protect donors. As different types of donation imply different risks for donors, with varying levels of significance, the monitoring of donor health should be proportionate to those levels of risk. This is particularly important when donation involves some risk to the donor’s health due to a need for pre-treatment with medicinal products, a medical intervention to collect the substance or a need for donors to donate repeatedly.
Amendment 155 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs, resulting from their human origin, and the increasing demands for these substances for human application or for the manufacture of products regulated by other Union legislation, or as the starting and raw material thereof, it is necessary to ensure a high level of health protection for donors as well as for recipients. SoHOs should be obtained from individuals whose health status is such that no detrimental effects will ensue as a result of the donation. This Regulation should therefore include principles and technical rules to monitor and protect donors. As different types of donation imply different risks for donors, with varying levels of significance, the monitoring of donor health should be proportionate to those levels of risk. This is particularly important
Amendment 156 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs, resulting from their human origin, and the increasing demands for these substances for human application or for the manufacture of products regulated by other Union legislation, or as the starting and raw material thereof, it is necessary to ensure a high level of health protection for donors as well as for recipients. SoHOs should be obtained from individuals whose health status is such that
Amendment 157 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs, resulting from their human origin, and the
Amendment 158 #
Proposal for a regulation Recital 13 (13) Given the special nature of SoHOs, resulting from their human origin, and the increasing demands for these substances for human application or for the manufacture of products regulated by other Union legislation, or as the starting and raw material thereof, it is necessary to ensure a high level of health protection for donors as well as for recipients. SoHOs
Amendment 159 #
Proposal for a regulation Recital 13 a (new) (13a) This regulation has no bearing on the right of offspring conceived during fertility treatment to know their provenance under the legislation in force in the Member States.
Amendment 160 #
Proposal for a regulation Recital 14 (14) When a harmful genetic condition is detected in the
Amendment 161 #
Proposal for a regulation Recital 15 (15) This Regulation does not prevent Member States from maintaining or introducing more stringent protective measures that are compatible with Union law
Amendment 162 #
Proposal for a regulation Recital 15 (15) This Regulation does not prevent Member States from maintaining or introducing more stringent protective measures that are compatible with Union law and founded on respect for human dignity, voluntary donation, and the principle that SoHOs cannot be used for financial gain. Member States should notify the Commission of any such measures. More stringent protective measures put in place by Member States should be evidence-
Amendment 163 #
Proposal for a regulation Recital 15 (15) This Regulation does not prevent Member States from maintaining or introducing more stringent protective measures that are compatible with Union
Amendment 164 #
Proposal for a regulation Recital 15 (15) This Regulation does not prevent Member States from maintaining or introducing more stringent protective measures that are compatible with Union law, particularly in the area of conception by means of fertility treatment. Member States should notify the Commission of any such measures. More stringent protective measures put in place by Member States should be evidence-
Amendment 165 #
Proposal for a regulation Recital 15 (15) This Regulation does not prevent Member States from maintaining or introducing more stringent protective measures that are compatible with Union law. Member States should notify the Commission of any such measures. More stringent protective measures put in place by Member States should be evidence- based and proportionate to the risk to human health, for example based on overall safety concerns and corresponding risks in a Member State or specific local risks. They should not discriminate against persons on grounds of sex, racial or ethnic origin, religion or belief, disability, age or sexual orientation, unless that measure or its application is objectively justified by a legitimate aim, and where necessary supported by scientific evidence, and the means of achieving that aim are appropriate and necessary.
Amendment 166 #
Proposal for a regulation Recital 15 (15) This Regulation does not prevent Member States from maintaining or introducing more stringent protective measures that are compatible with Union law. Member States should notify the Commission of any such measures. More stringent protective measures put in place by Member States should be evidence- based and proportionate to the risk to human health, for example based on overall safety concerns and corresponding risks in a Member State or specific local risks. They should not discriminate against persons on grounds of sex, racial or ethnic origin, religion or belief, disability, age or sexual orientation
Amendment 167 #
Proposal for a regulation Recital 15 (15) This Regulation does not prevent Member States from maintaining or introducing more stringent protective measures that are compatible with Union law. Member States should notify the Commission of any such measures. More stringent protective measures put in place by Member States should be evidence- based and proportionate to the risk to human health, for example based on overall safety concerns and corresponding risks in a Member State or specific local risks. They should not discriminate against persons on grounds of sex, racial or ethnic origin, religion or belief, disability, age or sexual orientation, unless that measure or
Amendment 168 #
Proposal for a regulation Recital 15 a (new) Amendment 169 #
Proposal for a regulation Recital 15 a (new) (15a) Human embryos and foetuses and their cells, tissues and organs must not be used for diagnostic, therapeutic, research or experimental purposes.
Amendment 170 #
Proposal for a regulation Recital 16 (16) This Regulation should not interfere with national legislation in the health area with objectives other than quality and safety of SoHOs that is compatible with Union law, in particular legislation concerning ethical aspects. Such aspects arise due to the human origin of the substances, which touches upon various sensitive and ethical concerns for Member States and citizens, such as access to particular services that use SoHOs. This
Amendment 171 #
Proposal for a regulation Recital 16 (16)
Amendment 172 #
Proposal for a regulation Recital 16 (16) This Regulation should not interfere with national legislation in the health area with objectives other than quality and safety of SoHOs that is compatible with Union law, in particular legislation concerning ethical aspects. Such aspects arise due to the human origin of the substances, which touches upon various sensitive and ethical concerns for Member States and citizens, such as access to particular services that use SoHOs. This Regulation should also not interfere with decisions of an ethical nature made by Member States, provided that they adhere to the Charter of Fundamental Rights of the European Union. Such ethical decisions might concern the use, or limitation of the use, of specific types of SoHOs or specific uses of SoHOs, including reproductive cells and embryonic stem cells. When a Member State allows the use of such cells, this Regulation should apply in full with a view to ensuring safety and quality and to protecting human health.
Amendment 173 #
Proposal for a regulation Recital 17 (17) This Regulation is not meant to cover research using SoHOs when that research does not involve application to the human body, for example in vitro research or research in animals. However, human substances used in research involving studies where they are applied to the human body should comply with the rules laid down in this Regulation, regarding clinical studies with SoHO.
Amendment 174 #
Proposal for a regulation Recital 18 (18) As a matter of principle, programmes promoting the donation of SoHOs should be founded on the principle of voluntary and unpaid donation, altruism of the donor and solidarity between donor and recipient.
Amendment 175 #
Proposal for a regulation Recital 18 (18) A
Amendment 176 #
Proposal for a regulation Recital 18 (18)
Amendment 177 #
Proposal for a regulation Recital 18 (18) As a matter of principle, programmes promoting the donation of SoHOs should be founded on the principle of voluntary and unpaid donation, altruism of the donor and solidarity between donor and recipient.
Amendment 178 #
Proposal for a regulation Recital 18 (18) As a matter of principle, programmes promoting the donation of SoHOs should be founded on the principle of voluntary and unpaid donation, altruism of the donor and solidarity between donor and recipient.
Amendment 179 #
Proposal for a regulation Recital 18 (18) As a matter of principle, programmes promoting the donation of SoHOs should be founded on the principle of voluntary and unpaid donation, altruism of the donor and solidarity between donor and recipient.
Amendment 180 #
Proposal for a regulation Recital 18 (18) As a matter of principle, programmes promoting the donation of SoHOs should be founded on the principle of voluntary and unpaid donation, altruism of the donor and solidarity between donor and recipient.
Amendment 181 #
Proposal for a regulation Recital 18 (18) As a matter of principle, programmes promoting the donation of SoHOs should be founded on the principle of voluntary and unpaid donation, altruism of the donor and solidarity between donor and recipient.
Amendment 182 #
Proposal for a regulation Recital 18 (18) As a matter of principle, programmes promoting the donation of SoHOs should be founded on the principle of voluntary and unpaid donation, altruism of the donor and solidarity between donor and recipient.
Amendment 183 #
Proposal for a regulation Recital 18 (18) As a matter of principle, programmes promoting the donation of SoHOs should be founded on the principle of voluntary and unpaid donation, altruism of the donor and solidarity between donor and recipient.
Amendment 184 #
Proposal for a regulation Recital 18 (18) As a matter of principle, programmes promoting the donation of SoHOs should be founded on the principle of voluntary and unpaid donation, altruism of the donor and solidarity between donor and recipient.
Amendment 185 #
Proposal for a regulation Recital 18 (18) As a matter of principle, programmes promoting the donation of SoHOs should be founded on the principle of voluntary and unpaid donation, altruism of the donor and solidarity between donor and recipient.
Amendment 186 #
Proposal for a regulation Recital 18 (18) As a matter of principle, programmes promoting the donation of SoHOs should be founded on the principle of voluntary and unpaid donation, altruism of the donor and solidarity between donor and recipient and may help to ensure the traceability of the donor. Voluntary and unpaid SoHO donation is also a factor which can contribute to ensuring the traceability of the donor and high safety standards for SoHOs and therefore to the protection of human health. It is also recognised, including by the Council of Europe Committee on Bioethics24, that while financial gain should be avoided, it may also be necessary to ensure that donors are not financially disadvantaged by their donation. Thus, compensation to remove any such risk is acceptable but should never constitute an incentive that would cause a donor to be dishonest when giving their medical or behavioural history or to donate more frequently than is allowed, posing risks to their own health and to that of prospective recipients. Such compensation should, therefore, be set by national authorities, at a level appropriate in their Member State to reach such objectives. _________________ 24 Council of Europe Committee on
Amendment 187 #
Proposal for a regulation Recital 18 (18)
Amendment 188 #
Proposal for a regulation Recital 18 (18) As a matter of principle, programmes promoting the donation of SoHOs should be founded on the principle of voluntary and unpaid donation, altruism of the donor and solidarity between donor and recipient.
Amendment 189 #
Proposal for a regulation Recital 19 (19) In order to maintain public trust in SoHO donation and use programmes, information that is given to prospective donors, recipients or physicians regarding the likely use and benefits of particular SoHOs or SoHO preparations when applied to recipients should accurately reflect reliable scientific evidence and under no circumstances attribute or imply levels of safety or efficacy not supported by scientific methods. This should ensure that donors, or their families, are not coerced to donate by exaggerated descriptions of benefits and prospective
Amendment 190 #
Proposal for a regulation Recital 20 (20) Competent authorities should be designated by the Member States for all the areas that fall within the scope of this Regulation. While Member States are best placed to identify the competent authority or authorities for each area, for example by geography, topic or substance, they should also be required to designate a single national authority that ensures appropriately coordinated communication with other Member States’ competent authorities and with the Commission. The SoHO National Authority should be considered the same as the designated competent authority in Member States where only one competent authority is designated. The list of all SoHO competent national authorities should be made publicly available.
Amendment 191 #
Proposal for a regulation Recital 20 (20) Competent authorities should be designated by the Member States for all the areas that fall within the scope of this Regulation. While Member States are best placed to identify the competent authority or authorities for each area, for example by geography, topic or substance, they sh
Amendment 192 #
Proposal for a regulation Recital 21 (21) For the performance of supervisory activities aimed at verifying the correct application of SoHO legislation, Member States should designate competent authorities that act independently and impartially. It is therefore important that their function of oversight is separate and independent from the performance of SoHO activities. In particular, competent authorities should be free from undue political influence and from industry interference that might affect their operational impartiality. In order to prevent such interference, it is advisable to make any appointment within these authorities incompatible with decision- making or management positions in the industry.
Amendment 193 #
Proposal for a regulation Recital 21 (21) For the performance of supervisory activities aimed at verifying the correct application of SoHO legislation, Member States should designate competent authorities that act independently and impartially. It is therefore important that their function of oversight is separate and independent from the performance of SoHO activities. In particular, competent authorities should be free from undue political influence and from industry or other actors’ interference that might affect their operational impartiality.
Amendment 194 #
Proposal for a regulation Recital 22 (22) For the performance of supervisory activities aimed at verifying the correct application of SoHO legislation, Member States should designate competent authorities that act in the public interest, are appropriately resourced and equipped, and offer guarantees of impartiality, professionalism and transparency. When infringements relate to direct health risks, and the publication of information regarding those infringements can contribute to risk mitigation and the protection of donors, recipients or offspring from medically assisted reproduction, competent authorities should, where necessary, be able to prioritise transparency of their enforcement activities over the protection of confidentiality of the party that has infringed the Regulation.
Amendment 195 #
Proposal for a regulation Recital 22 (22) For the performance of supervisory activities aimed at verifying the correct application of SoHO legislation, Member States should designate competent authorities – whose induction training they shall ensure – that act in the public interest, are appropriately resourced and equipped, and offer guarantees of impartiality, professionalism and transparency. When infringements relate to direct health risks, and the publication of information regarding those infringements can contribute to risk mitigation and the protection of donors, recipients or
Amendment 196 #
Proposal for a regulation Recital 22 a (new) (22a) For the performance of supervisory activities, competent authorities should ensure the impartiality and independence of the inspectors and provide them with training.
Amendment 197 #
Proposal for a regulation Recital 23 (23) The correct application and enforcement of the rules falling within the scope of this Regulation require an appropriate knowledge of those rules. It is therefore important that the staff performing supervisory activities have an appropriate professional background and are regularly trained, in accordance with their area of competence, on the obligations resulting from this Regulation, in order to make informed decisions and to be able to provide the target public with the correct information.
Amendment 198 #
Proposal for a regulation Recital 24 (24) When there is doubt about the regulatory status of a particular substance, product or activity under this Regulation, competent authorities should consult with the relevant authorities responsible for other relevant regulatory frameworks, namely medicinal products, medical devices, organs or food, with the aim of ensuring coherent procedures for the
Amendment 199 #
Proposal for a regulation Recital 24 (24) When there is doubt about the regulatory status of a particular substance, product or activity under this Regulation, competent authorities should consult
Amendment 200 #
Proposal for a regulation Recital 24 (24) When there is doubt about the regulatory status of a particular substance, product or activity under this Regulation, competent authorities should consult with the relevant authorities responsible for other relevant regulatory frameworks, namely medicinal products, medical devices, organs or food, with the aim of ensuring coherent procedures for the application of this Regulation. Competent authorities should inform the SoHO Coordination Board of the outcome of their consultations. When SoHOs or SoHO preparations are used to manufacture products regulated under other Union legislation, or as the starting and raw material thereof, competent authorities should cooperate with the relevant authorities on their territory. This cooperation should aim to reach an agreed approach for any subsequent communications between the authorities responsible for SoHO and for the other relevant sectors, as needed, regarding authorisation and monitoring of the SoHOs or the product manufactured from SoHOs. It should in principle be the responsibility of the Member States to decide on a case- by-case basis on the regulatory status of a substance, product or activity. However, in order to ensure consistent decisions across all Member States with regard to borderline cases, the Commission should be
Amendment 201 #
Proposal for a regulation Recital 24 (24) When there is doubt about the regulatory status of a particular substance, product or activity under this Regulation, competent authorities should consult with the relevant authorities responsible for other relevant regulatory frameworks, namely medicinal products, medical devices, organs or food, with the aim of ensuring coherent procedures for the application of this Regulation. Competent authorities should inform the SoHO Coordination Board of the outcome of their consultations. When SoHOs or SoHO preparations are used to manufacture products regulated under other Union legislation, or as the starting and raw material thereof, competent authorities should cooperate with the relevant authorities on their territory. This cooperation should aim to reach an agreed approach for any subsequent communications between the authorities responsible for SoHO and for the other relevant sectors, as needed, regarding authorisation and monitoring of the SoHOs or the product manufactured from SoHOs. It should in principle be the responsibility of the Member States to decide on a case- by-case basis on the regulatory status of a substance, product or activity. However, in order to ensure consistent decisions across all Member States with regard to
Amendment 202 #
Proposal for a regulation Recital 24 a (new) (24 a) Education in current science concerning SoHO application and transfusion as well as the whole process of SoHO procurement must receive more attention during formal mandatory medical training. Member States are encouraged to establish certain areas such as transfusion medicine as an independent medical subject with structured training, including medical speciality schools and programmes for continuous medical education for all medical staff. Training and better information of the prescribers would reduce the risk of unnecessary application of SoHO.
Amendment 203 #
Proposal for a regulation Recital 24 a (new) (24a) Health-care personnel should be informed about, and trained in, the functioning of the entire SoHO supply chain, in particular patient blood management, as recommended by the World Health Organization. Awareness- raising and continuous training for prescribers could avoid the application of SoHOs where therapeutic alternatives are available, in particular by ensuring the best possible use is made of SoHOs.
Amendment 204 #
Proposal for a regulation Recital 24 a (new) (24a) Given the World Health Organization's1 a recommendation that health-care personnel should be informed about, and trained in, patient blood management, prescribers should be made more aware of therapeutic alternatives to the application of this SoHO Regulation. This practice is also liable to limit the flow of SoHOs and ensure security of supply. _________________ 1 a World Health Organization Resolution WHA 63.12, ‘Availability, safety and quality of blood products’, 21.5.2010.
Amendment 205 #
Proposal for a regulation Recital 26 (26) Commission experts should have the necessary medical experience and knowledge to be able to perform controls, including audits, in Member States to verify the effective application of the relevant requirements of competent authorities and of the supervisory activity systems. Commission controls should also serve to investigate and collect information on enforcement practices or problems, emergencies and new developments in Member States. Official controls should be performed by personnel who are independent, free from any conflict of interest and in particular who are not in a situation which, directly or indirectly, could affect their ability to carry out their professional duties in an impartial manner.
Amendment 206 #
Proposal for a regulation Recital 26 (26) Commission experts should be able to perform controls, including audits, in Member States to verify the effective application of the relevant requirements of competent authorities and of the supervisory activity systems.
Amendment 207 #
Proposal for a regulation Recital 27 (27) Since SoHO preparations are subjected to a series of SoHO activities prior to their release and distribution, competent authorities should assess and authorise SoHO preparations to verify that a high level of safety, quality and efficacy is achieved consistently by the application of that specific series of activities, performed in that specific manner. When SoHOs are prepared with newly developed and validated collection, testing or processing methods, consideration should be given to the demonstration of safety and efficacy in recipients by means of requirements for clinical outcome data collection and review. The extent of such required clinical outcome data should correlate with the level of risk associated with the activities performed for that SoHO preparation and use. Where a new or modified SoHO preparation poses negligible risks for recipients (or
Amendment 208 #
Proposal for a regulation Recital 27 (27) Since SoHO preparations are subjected to a series of SoHO activities prior to their release
Amendment 209 #
Proposal for a regulation Recital 28 (28) Applicants requesting an authorisation of SoHO preparation should use the Euro GTP II methodologies or equivalent tools to assess the risk level of their SoHO preparation. Applicants should share the results of the risk assessments with competent authorities when requesting authorisation. With regard to SoHO preparations that pose a certain level of risk (low, moderate or high), the applicant should propose a plan for clinical outcome monitoring that should fulfil different requirements appropriate to the risk indicated. The most up-to-date guidance of the European Directorate for the Quality of Medicines & HealthCare (EDQM, a Directorate of the Council of Europe) should be considered relevant in the design of clinical follow-up studies proportionate in extent and complexity to the identified level of risk of the SoHO preparation. In the case of low risk, in addition to the mandatory continuous vigilance reporting, the applicant should organise proactive clinical follow-up for a defined number of patients. For moderate and high risk, in addition to the mandatory vigilance reporting and the clinical follow-up, the applicant should propose clinical investigation studies with monitoring of pre-defined clinical end-points. In case of high risk, these should include a comparison with standard treatments, ideally in a study with subjects allocated to test and control groups in a randomised manner. The competent authority should approve the plans before they are implemented and should assess the outcome data as part of a SoHO preparation authorisation.
Amendment 210 #
Proposal for a regulation Recital 28 (28) With regard to SoHO preparations that pose a certain level of risk (low, moderate or high), the applicant should propose a plan for clinical outcome monitoring that should fulfil different requirements appropriate to the risk indicated, following the guidelines specified in this Regulation. The most up- to-date guidance of the European Directorate for the Quality of Medicines & HealthCare (EDQM, a Directorate of the Council of Europe) should be considered relevant in the design of clinical follow-up studies proportionate in extent and complexity to the identified level of risk of the SoHO preparation. In the case of low risk, in addition to the mandatory continuous vigilance reporting, the applicant should organise proactive clinical follow-up for a defined number of patients. For moderate and high risk, in addition to the mandatory vigilance reporting and the clinical follow-up, the applicant should propose clinical investigation studies with monitoring of pre-defined clinical end- points. In case of high risk, these should include a comparison with standard treatments, ideally in a study with subjects allocated to test and control groups in a randomised manner. The competent authority should
Amendment 211 #
Proposal for a regulation Recital 28 (28) With regard to SoHO preparations that pose a certain level of risk (low, moderate or high), the applicant should propose a plan for clinical outcome monitoring that should fulfil different requirements appropriate to the risk indicated. The most up-to-date guidance of the European Directorate for the Quality of Medicines & HealthCare (EDQM, a Directorate of the Council of Europe) should be considered relevant in the design of clinical follow-up studies proportionate in extent and complexity to the identified level of risk of the SoHO preparation. In the case of low risk, in addition to the mandatory continuous vigilance reporting, the applicant should organise proactive clinical follow-up for a defined number of patients. For moderate and high risk, in addition to the mandatory vigilance reporting and the clinical follow-up, the applicant should propose clinical investigation studies with monitoring of
Amendment 212 #
Proposal for a regulation Recital 28 (28) With regard to SoHO preparations that pose a certain level of risk (low, moderate or high), the applicant should propose a plan for medium-term and long- term clinical outcome monitoring that should fulfil different requirements appropriate to the risk indicated. The most up-to-date guidance of the European Directorate for the Quality of Medicines & HealthCare (EDQM, a Directorate of the Council of Europe) should be considered relevant in the design of clinical follow-up studies proportionate in extent and complexity to the identified level of risk of the SoHO preparation. In the case of low risk, in addition to the mandatory continuous vigilance reporting, the applicant should organise proactive medium-term and long-term clinical follow-up for a defined number of
Amendment 213 #
Proposal for a regulation Recital 28 a (new) Amendment 214 #
Proposal for a regulation Recital 28 b (new) (28 b) The commitment to publish the clinical results obtained should be a mandatory requirement for clinical studies with SoHO. The existence of a registry of SoHO clinical studies at EU level is critical to facilitate patient participation in clinical studies, to boost multi-centre studies and to foster collaboration to generate more robust results and conclusions, and to make the generated knowledge available to other researchers, healthcare professionals, participants themselves and the general public.
Amendment 215 #
Proposal for a regulation Recital 29 (29) In the interests of efficiency, it should be permitted to conduct clinical outcome studies using the established framework in the pharmaceutical sector for clinical trials, as set out in Regulation (EU) No 536/2014 of the European Parliament and of the Council25, when operators wish to do so.
Amendment 216 #
Proposal for a regulation Recital 30 (30) In order to facilitate innovation and reduce administrative burden, competent authorities should share with each other information on the authorisation of new
Amendment 217 #
Proposal for a regulation Recital 30 (30) In order to facilitate innovation, identify the best solutions and preparations and reduce administrative burden, competent authorities should share with each other information on the authorisation of new SoHO preparations and the evidence used for such authorisations, including for the validation of certified medical devices used for SoHO collection, processing, storage or application to patients. Such sharing could allow authorities to accept previous authorisations granted to other entities, including in other Member States, to use these solutions and products for the benefit of recipients and to thus significantly reduce the requirements to generate evidence.
Amendment 218 #
Proposal for a regulation Recital 30 (30) In order to facilitate innovation and reduce administrative burden, competent authorities
Amendment 219 #
Proposal for a regulation Recital 31 (31) A broad range of public and private organisations influence the safety, quality and efficacy of SoHOs, even if they do not maintain banks of those SoHOs. Many organisations carry out a single SoHO activity, such as collection or donor testing on behalf of one or many organisations that maintain banks of SoHOs. The SoHO entity concept includes this broad range of organisations, from donor registries to
Amendment 220 #
Proposal for a regulation Recital 32 (32) Competent authorities should periodically review the SoHO entities registered in their territory and ensure that those entities that carry out both processing and storage of SoHOs are inspected and authorised as SoHO establishments before starting those activities. A SoHO establishment authorisation should refer to the legal entity, even when one SoHO establishment has many physical sites. Competent authorities should consider the impact on safety, quality and efficacy of the SoHO activities carried out at SoHO entities that do not meet the definition of a SoHO establishment and decide whether particular entities should be subject to establishment authorisations due to the risk or scale associated with their activities. Similarly, SoHO entities that have a poor record in terms of compliance with reporting or other obligations might be suitable candidates for authorisation as SoHO establishments.
Amendment 221 #
Proposal for a regulation Recital 33 (33) With regards to standards concerning donor, recipient and offspring protection, this Regulation should provide for a hierarchy of rules for their implementation. As risks and technologies change, this hierarchy of rules should facilitate an efficient and responsive uptake of the most up-to-date guidelines for implementing the standards set out in this Regulation. As part of that hierarchy, in the absence of Union legislation describing particular procedures to be applied and followed to meet the standards set out in this Regulation, following the guidelines of the European Centre for Disease Prevention and Control (ECDC) and the EDQM should be considered as a means to demonstrate compliance with the standards laid down in this Regulation to ensure high level of quality, safety and efficacy. Member States should be involved in both the drafting and voting of these guidelines and should follow a transparent process of consultation with other relevant EU authorities and stakeholders. SoHO entities should be permitted to follow other guidelines, provided that it has been demonstrated that those other guidelines are based on the most up-to-date scientific evidence and achieve the same level of quality, safety and efficacy. In cases of detailed technical issues for which neither Union legislation nor the ECDC and the EDQM have defined a technical guideline or rule, operators should apply a locally defined rule that is in line with relevant internationally recognised guidelines and scientific evidence and is appropriate to mitigate any risk identified.
Amendment 222 #
Proposal for a regulation Recital 33 (33) With regards to standards concerning donor, recipient and offspring protection, this Regulation should provide for a hierarchy of rules for their implementation. As risks and technologies change, this hierarchy of rules should facilitate an efficient and responsive uptake of the most up-to-date guidelines for implementing the standards set out in this Regulation. As part of that hierarchy, in the absence of Union legislation describing particular procedures to be applied and followed to meet the standards set out in this Regulation, following the guidelines of the European Centre for Disease Prevention and Control (ECDC) and the EDQM should be considered as a means to demonstrate compliance with the standards laid down in this Regulation to ensure high level of quality, safety and efficacy. SoHO entities should be permitted to follow other guidelines, provided that it has been demonstrated that those other guidelines achieve the same level of quality, safety and efficacy. In cases of detailed technical issues for which neither Union legislation nor the ECDC and the EDQM have defined a technical guideline or rule, operators should apply a locally defined rule that is in line with relevant internationally recognised guidelines and scientific evidence and is appropriate to mitigate any risk identified. When assesing scientific guidlines, it is important that the Commission, the ECDC, and the EDQM involve existing scientific, donor, and patient representative groups.
Amendment 223 #
Proposal for a regulation Recital 33 (33) With regards to standards concerning donor, recipient and offspring protection, this Regulation should provide for a hierarchy of rules for their implementation. As risks and technologies change, this hierarchy of rules should facilitate an efficient and responsive uptake of the most up-to-date guidelines based on scientific evidence for implementing the standards set out in this Regulation. As part of that hierarchy, in the absence of Union legislation describing particular procedures to be applied and followed to meet the standards set out in this Regulation, following the guidelines of the European Centre for Disease Prevention and Control (ECDC) and the EDQM should be considered as a means to demonstrate compliance with the standards laid down in this Regulation to ensure high level of quality, safety and efficacy. SoHO entities should be permitted to follow other guidelines, provided that it has been demonstrated that those other guidelines achieve the same level of quality, safety and efficacy. In cases of detailed technical issues for which neither Union legislation nor the ECDC and the EDQM have defined a technical guideline or rule, operators should apply a locally defined rule that is in line with relevant internationally recognised guidelines and scientific evidence and is appropriate to mitigate any risk identified.
Amendment 224 #
Proposal for a regulation Recital 33 (33) With regards to standards concerning donor, recipient and offspring protection, this Regulation should provide for a hierarchy of rules for their implementation. As risks and technologies change, this hierarchy of rules should facilitate an efficient and responsive uptake of the most up-to-date guidelines based on scientific evidence for implementing the standards set out in this Regulation. As part of that hierarchy, in the absence of Union legislation describing particular procedures to be applied and followed to meet the standards set out in this Regulation, following the guidelines of the European Centre for Disease Prevention and Control (ECDC) and the EDQM should be
Amendment 225 #
Proposal for a regulation Recital 33 (33) With regards to standards concerning donor, recipient and offspring protection, this Regulation should provide for a hierarchy of rules for their implementation. As risks and technologies change, this hierarchy of rules should facilitate an efficient and responsive uptake of the most up-to-date guidelines for implementing the standards set out in this Regulation. As part of that hierarchy, in the absence of Union legislation describing particular procedures to be applied and followed to meet the standards set out in this Regulation, following the guidelines of the European Centre for Disease Prevention and Control (ECDC) and the EDQM should be
Amendment 226 #
Proposal for a regulation Recital 33 (33) With regards to standards concerning donor, recipient and offspring protection, this Regulation should provide for a hierarchy of rules for their implementation. As risks and technologies change, this hierarchy of rules should facilitate an efficient and responsive uptake of the most up-to-date guidelines for implementing the standards set out in this Regulation. As part of that hierarchy, in the absence of Union legislation describing particular procedures to be applied and followed to meet the standards set out in this Regulation, following the guidelines of the European Centre for Disease Prevention and Control (ECDC) and the EDQM should be considered as
Amendment 227 #
Proposal for a regulation Recital 33 a (new) (33 a) It is important that the Commission, the ECDC, the EDQM, when assessing scientific guidelines to be implemented at the Union level, involve, when appropriate existing professional, scientific, donor and patient representative groups at Union level in the field of SoHOs.
Amendment 228 #
Proposal for a regulation Recital 34 (34) Where evidence demonstrates that specific processing steps reduce or eliminate the risk of transmission of specific infectious or non-infectious disease agents, the quality and safety standards for the verification of donor eligibility by means of donor health evaluations, including testing, and the related guidelines for their implementation, should take this evidence into account. Thus, in the case of, for example, plasma for fractionation, that in a subsequent step in the manufacturing process of medicinal products undergoes sterilisation steps,
Amendment 229 #
Proposal for a regulation Recital 35 (35) The EDQM is a structural part of the Council of Europe working under the European Pharmacopoeia Partial Agreement. The text of the Convention on the elaboration of a European Pharmacopoeia (ETS No. 050), accepted by Council Decision 94/358/EC26, is considered to be the text of the European Pharmacopoeia Partial Agreement. Member States of the Council of Europe that have signed and ratified the European Pharmacopoeia Convention are
Amendment 230 #
Proposal for a regulation Recital 35 (35) The EDQM is a structural part of the Council of Europe working under the European Pharmacopoeia Partial Agreement. The text of the Convention on the elaboration of a European Pharmacopoeia (ETS No. 050), accepted by Council Decision 94/358/EC26, is considered to be the text of the European Pharmacopoeia Partial Agreement. Member States of the Council of Europe that have signed and ratified the European Pharmacopoeia Convention are the member States of the European Pharmacopoeia Partial Agreement and are therefore the members of the intergovernmental bodies functioning within the framework of this partial agreement, including among others: the European Pharmacopoeia Commission, the European Committee on Organ Transplantation (CD-P-TO), the European Committee on Blood Transfusion (CD-P- TS) and the European Committee on Pharmaceuticals and Pharmaceutical Care (CD-P-PH). The European Pharmacopoeia Convention has been signed and ratified by the European Union and all its Member States, all of whom are represented in their intergovernmental bodies. In this context, the work of the EDQM on developing and updating guidelines on safety and quality of blood, tissues and cells, should be considered an important contribution to the field of SoHOs in the Union and should be reflected in this Regulation. The guidelines address issues of quality and safety beyond the risks of communicable disease transmission, such as donor eligibility criteria for the prevention of the transmission of cancer and other non- communicable diseases and the assurance of safety and quality during collection, processing, storage and distribution. It should therefore be possible to use those guidelines as one of the means to
Amendment 231 #
Proposal for a regulation Recital 35 (
Amendment 232 #
Proposal for a regulation Recital 35 (35) The EDQM is a structural part of the Council of Europe working under the European Pharmacopoeia Partial Agreement. The text of the Convention on the elaboration of a European Pharmacopoeia (ETS No. 050), accepted by Council Decision 94/358/EC26, is considered to be the text of the European Pharmacopoeia Partial Agreement. Member States of the Council of Europe that have signed and ratified the European Pharmacopoeia Convention are the member States of the European Pharmacopoeia Partial Agreement and are therefore the members of the intergovernmental bodies functioning within the framework of this partial agreement, including among others: the European Pharmacopoeia Commission, the European Committee on Organ Transplantation (CD-P-TO), the European Committee on Blood Transfusion (CD-P- TS) and the European Committee on Pharmaceuticals and Pharmaceutical Care (CD-P-PH). The European Pharmacopoeia Convention has been signed and ratified by the European Union and all its Member States, all of whom are represented in their intergovernmental bodies. In this context, the work of the EDQM on developing and updating guidelines on safety and quality of blood, tissues and cells, should be considered an important contribution to the field of SoHOs in the Union and should be reflected in this Regulation. The guidelines address issues of quality and safety beyond the risks of communicable disease transmission, such as donor eligibility criteria for the prevention of the transmission of cancer and other non- communicable diseases and the assurance of safety and quality during collection,
Amendment 233 #
Proposal for a regulation Recital 35 (35) The EDQM is a structural part of the Council of Europe working under the European Pharmacopoeia Partial Agreement. The text of the Convention on the elaboration of a European Pharmacopoeia (ETS No. 050), accepted by Council Decision 94/358/EC
Amendment 234 #
Proposal for a regulation Recital 35 (35) The EDQM is a structural part of the Council of Europe working under the European Pharmacopoeia Partial Agreement. The text of the Convention on the elaboration of a European Pharmacopoeia (ETS No. 050), accepted by Council Decision 94/358/EC26, is considered to be the text of the European Pharmacopoeia Partial Agreement. Member States of the Council of Europe that have signed and ratified the European Pharmacopoeia Convention are the member States of the European Pharmacopoeia Partial Agreement and are therefore the members of the intergovernmental bodies functioning within the framework of this partial agreement, including among others: the European Pharmacopoeia Commission, the European Committee on Organ Transplantation (CD-P-TO), the European Committee on Blood Transfusion (CD-P- TS) and the European Committee on Pharmaceuticals and Pharmaceutical Care (CD-P-PH). The European Pharmacopoeia Convention has been signed and ratified by the European Union and all its Member States, all of whom are represented in their intergovernmental bodies. In this context, the work of the EDQM on developing and updating guidelines on safety and quality of blood, tissues and cells, should be considered an important contribution to the field of SoHOs in the Union and should be reflected in this Regulation. The guidelines address issues of quality and safety beyond the risks of communicable disease transmission, such as donor eligibility criteria for the prevention of the transmission of cancer and other non- communicable diseases and the assurance
Amendment 235 #
Proposal for a regulation Recital 35 (35) The EDQM is a structural part of the Council of Europe working under the European Pharmacopoeia Partial Agreement. The text of the Convention on the elaboration of a European Pharmacopoeia (ETS No
Amendment 236 #
Proposal for a regulation Recital 36 (36) The ECDC, established by Regulation (EC) No 851/2004 of the European Parliament and of the Council27, is a Union agency with the mission of strengthening Europe's defences against communicable diseases. The work of the ECDC on developing and updating guidelines on safety and quality of SoHOs from a communicable disease threat perspective, should be considered an important contribution in the field of SoHOs in the Union and should be reflected in this Regulation. In addition, the ECDC established an expert network for the Microbial Safety of SoHOs, which ensures the implementation of the requirements on the ECDC’s relations with the Union Member States and EEA Member States stated in Regulation (EC) No 851/2004, regarding strategic and operational collaboration on technical and scientific issues, surveillance, responses to health threats, scientific opinions, scientific and technical assistance, collection of data, identification of emerging health threats, and public information campaigns related to the safety of SoHOs. This SoHO expert network should provide information or advice in relation to relevant outbreaks of communicable diseases, in particular regarding the eligibility and testing of donors and the investigation of serious adverse occurrences involving suspected transmission of a communicable disease. In order to comply with the Union requirements for review of Union legislation, a transparent and participatory stakeholder consultation process shall be put in place for the development of those provisions and guidelines from the expert bodies.The committees referred to and any working parties and scientific advisory groups established within those committees shall develop appropriate contacts with public and private key stakeholders, including patients, consumers, health professionals, and industry representatives. _________________ 27 Regulation (EC) No 851/2004 of the
Amendment 237 #
Proposal for a regulation Recital 36 (36) The ECDC, established by Regulation (EC) No 851/2004 of the European Parliament and of the Council27, is a Union agency with the mission of strengthening Europe's defences against communicable diseases. The work of the ECDC on developing and updating guidelines on safety
Amendment 238 #
Proposal for a regulation Recital 36 (36) The ECDC, established by Regulation (EC) No 851/2004 of the European Parliament and of the Council 27
Amendment 239 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States and the Union should promote the
Amendment 240 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. To ensure long-term sustainability, the campaigns should primarily focus on increasing the donor base for low-frequency donations. As there is a need to ensure the availability of SoHOs for medical treatments, Member States should support the establishment of public donation facilities and promote the donation of SoHOs, including plasma, of high quality and safety, thereby also increasing the collection capacity and self- sufficiency in the Union. Member States are also urged to take steps to encourage a strong public and non-profit sector involvement in the provision of SoHO services, in particular for critical SoHOs and the related research and development.
Amendment 241 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States should promote the donation of SoHOs, including plasma, of high quality and safety, thereby also increasing self- sufficiency in the Union. Member States are also urged to take steps to encourage a strong public and non-profit sector involvement in the provision of SoHO services, in particular for critical SoHOs and the related research and development. Where SoHO is the starting material, such as with plasma derived medicinal products, a more comprehensive reflection over the overall supply chain is needed to ensure equitable patient access to these products.
Amendment 242 #
(37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States and the Union should promote the donation of
Amendment 243 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States should promote the donation of SoHOs, including plasma, of high quality and safety, thereby also increasing self- sufficiency in the Union. Member States are also urged to take steps to encourage a strong public and non-profit sector involvement in the provision of SoHO services, in particular for critical SoHOs and the related research and development. Such services should prevent the fragmentation of SoHO supply among multiple suppliers without certainty that all products, including rare ones, remain accessible to all patients.
Amendment 244 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance
Amendment 245 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to ensuring the broadest possible doner base and to help European citizens to decide whether to become donors during
Amendment 246 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States and the Union should promote the donation of SoHOs, including plasma, of high quality and safety, thereby also increasing
Amendment 247 #
Proposal for a regulation Recital 37 (37) It is necessary and beneficial to all parties to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States should promote the donation of SoHOs, including plasma, of high quality and safety, thereby also increasing self-
Amendment 248 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States should promote the donation of SoHOs, including plasma, of high quality and safety, thereby also increasing self- sufficiency in the Union. Member States are also urged to take steps to encourage
Amendment 249 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States should promote the donation of SoHOs,
Amendment 250 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States should promote the donation of SoHOs, including plasma, of high quality and safety, thereby also increasing self- sufficiency in the Union. Member States are also urged to take steps to encourage
Amendment 251 #
(37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States should promote the donation of SoHOs, including plasma, of high quality and safety, thereby also increasing self- sufficiency in the Union. Member States are also urged to take steps to encourage
Amendment 252 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to
Amendment 253 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States should promote the donation of SoHOs, including plasma, of high quality and safety, thereby also increasing self- sufficiency in the Union. Member States are also urged to take steps to encourage
Amendment 254 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States should promote the donation of SoHOs, including plasma, of high quality and safety, thereby also increasing self- sufficiency in the Union. Member States are also urged to take steps to encourage a strong
Amendment 255 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance
Amendment 256 #
Proposal for a regulation Recital 37 (37) It is necessary to promote information and awareness campaigns at national and Union level on the importance of SoHOs. The aim of these campaigns should be to help European citizens to decide whether to become donors during their lifetime and let their families or legal representatives know their wishes regarding donation after death. As there is a need to ensure the availability of SoHOs for medical treatments, Member States should promote the donation of SoHOs,
Amendment 257 #
Proposal for a regulation Recital 37 a (new) Amendment 258 #
Proposal for a regulation Recital 37 a (new) (37 a) The COVID-19 pandemic has had adverse effects on the resilience of the donor base in some countries, whose collection systems rely on a small number of donors donating more frequently than elsewhere. These adverse effects are particularly evident in plasma collections and imports. Member States are urged to develop non-profit and public plasmapheresis programs in order to increase their collection capacity. This will make the donor base more resilient by expanding it as far as possible and, as a result, it will ensure the continuity of supply, including in times of crisis.
Amendment 259 #
Proposal for a regulation Recital 37 a (new) (37 a) As recommended by the World Health Organisation (WHO), Member States should additionally support optimal clinical use of SoHOs, particularly where there are alternatives which can reduce the demand for SoHOs. In such fashion, Member States should ensure efficient implementation of the Patient Blood Management (PBM), which improves patients’ safety by minimising the risks associated with transfusion and improve patient outcomes, while at the same time ensuring sufficiency of blood supplies and reducing financial pressure on health system.
Amendment 260 #
Proposal for a regulation Recital 37 a (new) (37a) Given the negative effects of the COVID-19 pandemic on the frequency and quantity of plasma donation in some countries, Member States are invited to develop plasmapheresis programmes to increase their collection capacity and donor base.
Amendment 261 #
Proposal for a regulation Recital 37 a (new) (37 a) Member States are encouraged to develop or strengthen plasmapheresis programmes to ensure capacity to collect more plasma and the Commission shall assist them in this task by providing guidance and facilitating the exchange of best practices.
Amendment 262 #
Proposal for a regulation Recital 37 a (new) (37 a) To ensure the capacity to better collect more plasma, Member States are encouraged to develop or strengthen their respective plasmapheresis programs. The Commission shall aid them through guidance and the exchange of best practices.
Amendment 263 #
Proposal for a regulation Recital 37 b (new) (37 b) In order to ensure self-sufficiency and sustainability of supply of SoHOs, Member States should establish national SoHO emergency plans setting out measures when the supply situation for critical SoHOs presents or is likely to present a serious risk to human health. Such plans shall include measures, including optimisation of use, that impact demand of critical SoHOs, targets to ensure self-sufficiency of supply of critical SoHOs, donor recruitment and retainment strategy and ways of cooperation between competent authorities, experts and relevant stakeholders. National emergency plans should be further supplemented by the EU Strategy for critical SoHO supply sufficiency, primarily focusing on supply monitoring, reporting obligations and sharing of best practices within the EU.
Amendment 264 #
Proposal for a regulation Recital 37 b (new) (37 b) On the other hand, it is essential to take steps to achieve, as soon as possible, an EU autonomy in the area of SoHO, especially in the case of plasma, which shows an increasing demand due to new therapeutic applications of plasma- derived medicines. Nowadays, the Union suffers from chronic shortages of plasma, resulting in its dependence on imports from third countries. It is necessary to specify the measures to be taken to increase the donor base, always in line with the principles of voluntary and unpaid donation, as well as to improve the infrastructure to enable efficient collection of SoHO, in order to ensure the continued, adequate and safe supply, also in times of crisis.
Amendment 265 #
Proposal for a regulation Recital 37 b (new) (37 b) The loss of European sovereignty in the area of public health was thrown into sharp relief during the COVID-19 crisis. In this context, the initiatives for a strong Europe of Health should work in favour of European self-sufficiency, in particular as regards the supply of SoHOs and the ability to minimise the risk of shortages, especially of SoHOs for therapeutic use. Following the publication of the strategy for the promotion of European ethical SoHO supply self- sufficiency, Member States should adopt national priority action programmes for donor recruitment via voluntary unpaid donation.
Amendment 266 #
Proposal for a regulation Recital 37 c (new) (37 c) In order to reach an appropriate level of autonomy in the Union, it will be necessary to increase the collection of SoHO, but also to ensure its proper and efficient use. The factors and measures affecting SoHO’s demand play a critical role in ensuring the quality, safety and sustainability of the SoHO system. Suboptimal clinical practices and unnecessary use of SoHO compromises patient safety and limits the availability of SoHO for other patients in need. Member States should take measures to promote the optimal use of SoHO, taking into account alternatives that may reduce the demand, always following the most up-to- date scientific guidelines. The competent authorities should train healthcare professionals to make optimal use of SoHO. Member States should draw up national plans to ensure the supply of SoHO, as well as national emergency plans.
Amendment 267 #
Proposal for a regulation Recital 37 d (new) (37 d) In cases where the availability of SoHO preparations or SoHO-derived products depend on profit-making entities, such as some plasma-derived products, there is a risk of altruistic donations turning into disproportionate profits and commercial interests taking precedence over the interests of patients and research. There could even be situations in which some low-profitable products are no longer produced, hampering their accessibility for patients. Similarly, investment in research and innovation for this type of products could be very small or non-existent. Prices of SoHO-derived products, which are obtained from altruistic and unpaid donations, should be fair and transparent. For certain low- profitable products, Member States should encourage research and innovation and should ensure, through negotiations, incentives or public service obligations, that they continue to be manufactured.
Amendment 268 #
Proposal for a regulation Recital 38 (38) In order to promote a coordinated application of this Regulation, a SoHO Coordination Board (SCB) should be set up. The Commission should participate in its activities and chair it. The SCB should contribute to a coordinating the application of this Regulation throughout the Union, including by helping Member States to conduct SoHO supervisory activities. The SCB should be composed of persons designated by the Member States based on their role and expertise in their competent authorities, and should also involve experts that are not working for competent authorities, for specific tasks where access to necessary in-depth technical expertise in the field of SoHOs is required. In the latter case, appropriate consideration should be given to the possibility of involving European expert agencies and bodies such as the ECDC
Amendment 269 #
Proposal for a regulation Recital 38 (38) In order to promote a coordinated application of this Regulation, a SoHO Coordination Board (SCB) should be set up. The Commission should participate in its activities and chair it. The SCB should contribute to a coordinating the application of this Regulation throughout the Union, including by helping Member States to conduct SoHO supervisory activities. The SCB should be composed of persons designated by the Member States based on their role and expertise in their competent authorities, and should also involve experts that are not working for competent authorities, for specific tasks where access to necessary in-depth technical expertise in the field of SoHOs is required. In the latter case, appropriate consideration should be given to the possibility of involving European expert bodies such as the ECDC and the EDQM and existing professional, scientific and donor and patient representative groups at Union level in the field of SoHOs. The SCB should adhere to high degree of transparency of its outputs and all it members, observers and experts should act independently, in the public interest and be free from any external influence that might affect the impartiality of their professional conduct.
Amendment 270 #
Proposal for a regulation Recital 38 (38) In order to promote a coordinated application of this Regulation, a SoHO Coordination Board (SCB) should be set up. The Commission should participate in its activities and chair it. The SCB should contribute to a coordinating the application of this Regulation throughout the Union, including by helping Member States to conduct SoHO supervisory activities. The SCB should be composed of persons designated by the Member States based on their role and expertise in their competent authorities, and should also involve experts that are not working for competent authorities, for specific tasks where access to necessary in-depth technical expertise in the field of SoHOs is required. In the latter case, appropriate consideration should be given to the possibility of involving European expert bodies such as the ECDC and the EDQM and existing professional, scientific and donor and patient representative groups and industry experts at Union level in the field of SoHOs. When seeking the input of expert bodies such as the ECDC and the EDQM, the SCB shall have due regard to their respective areas of expertise and avoid duplication.
Amendment 271 #
Proposal for a regulation Recital 38 (38) In order to promote a coordinated application of this Regulation, a SoHO Coordination Board (SCB) should be set up. The Commission should participate in its activities and chair it. The SCB should contribute to a coordinating the application of this Regulation throughout the Union, including by helping Member States to conduct SoHO supervisory activities. The SCB should be composed of persons designated by the Member States based on their role and expertise in their competent authorities, and should also involve experts that are not working for competent authorities, for
Amendment 272 #
Proposal for a regulation Recital 38 (38) In order to promote a coherent and coordinated application of this Regulation, a SoHO Coordination Board (SCB) should be set up. The Commission should participate in its activities and chair it. The SCB should contribute to a coordinating the application of this Regulation throughout the Union,
Amendment 273 #
Proposal for a regulation Recital 38 a (new) (38 a) The Commission shall cooperate with the EDQM in relation to the guidelines issued by that body. Such cooperation is without prejudice to the autonomy of Union law and should take into account Union principles on transparency and stakeholder participation.
Amendment 274 #
Proposal for a regulation Recital 39 (39) Some substances, products or activities have been subject to different legal frameworks with different requirements in the Member States. This may sometimes cause
Amendment 275 #
Proposal for a regulation Recital 39 (39) Some substances, products or activities have been subject to different legal frameworks with different requirements in the Member States. This causes confusion among operators in the field, and the consequent legal uncertainty is a disincentive to professionals to develop new ways to prepare and use SoHOs. In case a product could be classified both as SoHO or SoHO preparation and medicinal product, the classification as medicinal product should prevail.The SCB should receive relevant information on national decisions made on cases where questions were raised on the regulatory status of SoHOs. The SCB should keep a compendium of the opinions issued by the SCB or the competent authorities and of decisions made at Member State level, so that competent authorities considering the regulatory status under this Regulation of a particular substance, product or activity may inform their decision-making process by referring to that compendium. The SCB should also document agreed best practices to support a common Union approach. It should also cooperate with similar Union level bodies established in other Union legislation with a view to facilitating coordinated and coherent application of this Regulation between Member States and across bordering legislative frameworks. These measures should promote a coherent cross-sectoral approach, ensure high protection of public health, and facilitate
Amendment 276 #
Proposal for a regulation Recital 39 (39) Some substances, products or activities have been subject to different legal frameworks with different requirements in the Member States. This causes confusion among operators in the field, and the consequent legal uncertainty is a disincentive to professionals to develop new ways to prepare and use SoHOs. The SCB should receive ongoing and constant relevant information on national decisions made on cases where questions were raised on the regulatory status of SoHOs. The SCB should monitor these opinions in order to react quickly and in an informed manner to further requests for opinions from other Member States, keep a compendium of the opinions issued by the SCB or the competent authorities and of decisions made at Member State level, so that competent authorities considering the regulatory status under this Regulation of a particular substance, product or activity may inform their decision-making process by referring to that compendium. The SCB should also document agreed best practices to support a common Union approach. It should also cooperate with similar Union level bodies established in other Union legislation with a view to facilitating coordinated and coherent application of this Regulation between Member States and across bordering legislative frameworks. These measures should promote a coherent cross- sectoral approach and facilitate SoHO innovation.
Amendment 277 #
Proposal for a regulation Recital 39 (39) Some substances, products or activities have been subject to different legal frameworks with different requirements in the Member States. This causes confusion among operators in the field, and the consequent legal uncertainty is a disincentive to professionals to develop new ways to prepare and use SoHOs. The SCB should receive relevant information on national decisions made on cases where questions were raised on the regulatory status of SoHOs. The SCB should keep a compendium of the opinions issued by the SCB, the Classification Advisory Council or the competent authorities and of decisions made at Member State level, so that competent authorities considering the regulatory status under this Regulation of a particular substance, product or activity may inform their decision-making process by referring to that compendium. The SCB should also document agreed best practices to support a common Union approach. It should also cooperate with similar Union level bodies established in other Union legislation with a view to facilitating coordinated and coherent application of this Regulation between Member States and across bordering legislative frameworks. These measures should promote a coherent cross-sectoral approach and facilitate SoHO innovation.
Amendment 278 #
Proposal for a regulation Recital 40 (40) The concept of a plasma master file (PMF) was established in Commission Directive 2003/63/EC28. Since that
Amendment 279 #
Proposal for a regulation Recital 41 (41) In order to limit administrative burden on competent authorities and the Commission, the latter should establish an online platform (the ‘EU SoHO Platform’) to facilitate timely submission of data and reports as well as improved transparency of national reporting and supervisory activities. The EU SoHO Platform might also be utilized by Member States as a channel for national initiatives and campaigns to encourage the exchange of best practices. Said national campaigns and campaigns shall, in close cooperation with patient organizations, aim to promote donation and sustainable supplies of SoHO products.
Amendment 280 #
Proposal for a regulation Recital 41 (41) In order to limit administrative burden on competent authorities and the Commission, the latter should establish an online platform (the ‘EU SoHO Platform’) to facilitate timely submission of data and reports as well as improved transparency of national reporting and supervisory activities. The EU SoHO Platform should also serve as a reliable source of information for the general public regarding the work of the SoHO Coordination Board, national competent authorities and other expert bodies, including the EDQM, and SoHO entities and establishments.
Amendment 281 #
Proposal for a regulation Recital 41 (41) In order to limit administrative burden on competent authorities and the Commission, the latter should establish an online platform (the ‘EU SoHO Platform’) to facilitate timely submission of data and reports as well as improved transparency of national reporting and supervisory activities
Amendment 282 #
Proposal for a regulation Recital 41 (41) In order to limit administrative burden on competent authorities and the Commission, the latter should establish an online platform (the ‘EU SoHO Platform’) to facilitate timely submission of data and reports as well as improved transparency of national reporting and supervisory activities. The online platform could be further used for the sharing of best practice between Member States with regard to initatives, such as campaigns, to support the supply of SoHOs.
Amendment 283 #
Proposal for a regulation Recital 41 (41) In order to limit administrative burden on competent authorities and the Commission, the latter should establish an online platform (the ‘EU SoHO Platform’) to facilitate timely submission of data and reports
Amendment 284 #
Proposal for a regulation Recital 41 (41) In order to limit administrative burden on competent authorities and the Commission, the latter should establish an online platform (the ‘EU SoHO Platform’) to facilitate timely submission of data and reports and the centralisation of this data in order to apply the most viable solutions, as well as improved transparency of national reporting and supervisory activities.
Amendment 285 #
Proposal for a regulation Recital 42 (42) The processing of personal data under this Regulation should be subject to strict guarantees of confidentiality and should comply with the rules on the protection of personal data laid down in Regulation (EU) 2016/679 of the European Parliament and of the Council and in Regulation (EU) 2018/1725 of the European Parliament and of the Council
Amendment 286 #
Proposal for a regulation Recital 43 (43) As the EU SoHO Platform requires the processing of personal data, it will be designed respecting the principles of data protection. Any processing of personal data should be limited to achieving the objectives and obligations of this Regulation. Access to the EU SoHO Platform, once established, should be granted within the framework of the European Health Data Space (EHDS) and otherwise should be limited to the extent necessary to carry out supervisory activities provided for in this Regulation.
Amendment 287 #
Proposal for a regulation Recital 43 (43) As the EU SoHO Platform requires the processing of personal data, it will be
Amendment 288 #
Proposal for a regulation Recital 43 (43) As the EU SoHO Platform requires the processing of personal data, it will be designed respecting the principles of data protection. Any processing of personal data should be limited to achieving the objectives and obligations of this Regulation. Access to the EU SoHO Platform should be limited to the extent necessary to carry out supervisory activities provided for in this Regulation. In addition, the personal data and curriculum vitae of the persons responsible for the release of SoHOs should not be made public.
Amendment 289 #
Proposal for a regulation Recital 43 (43) As the EU SoHO Platform requires the processing of personal data, it will be designed respecting the principles of data protection. Any processing of personal data should be limited to achieving the objectives and obligations of this Regulation. Access to the EU SoHO Platform should, once it is established, be granted within the framework of the European Health Data Space and otherwise be limited to the extent necessary to carry out supervisory activities provided for in this Regulation.
Amendment 290 #
Proposal for a regulation Recital 43 (43) As the EU SoHO Platform requires the processing of personal data, it will be designed respecting the principles of data protection laid down in Article 5 of Regulation (EU) 2016/679. Any processing of personal data should be limited to achieving the objectives and obligations of this Regulation. Access to the EU SoHO Platform should be limited to the extent necessary to carry out supervisory activities provided for in this Regulation.
Amendment 291 #
Proposal for a regulation Recital 44 (44) This Regulation respects the fundamental rights and observes the principles recognised in particular by the Charter of Fundamental Rights of the European Union and in particular human dignity, the integrity of the person
Amendment 292 #
Proposal for a regulation Recital 44 (44) This Regulation respects the fundamental rights and observes the principles recognised in particular by the Charter of Fundamental Rights of the European Union and in particular human dignity, the prohibition of making the human body and its parts a source of economic gain, the integrity of the person, the protection of personal data, the freedom of art and science and to conduct business, non-discrimination, the right to health protection and access to health care, and the rights of the child. To achieve these aims, all supervisory and SoHO activities should always be carried out in a manner that fully respects those rights and principles. The right for dignity and integrity of donors, recipients and of offspring born from medically assisted reproduction should always be taken into account, amongst others, by ensuring that consent for donation is freely given and donors or their representatives are informed with regards to the intended use of the donated material, that donor eligibility criteria are based on scientific evidence, that the use of SoHOs in humans is not promoted for commercial purposes or with false or misleading information regarding efficacy so that the donors and recipients can make well-informed and deliberate choices, that activities are conducted in a transparent manner that prioritises the safety of donors and recipients, and that allocation and equitable and non-discriminatory access to SoHOs are defined in a transparent manner, on the basis of an objective evaluation of medical needs. This Regulation should therefore be applied
Amendment 293 #
Proposal for a regulation Recital 44 (44) This Regulation respects the fundamental rights and observes the principles recognised in particular by the Charter of Fundamental Rights of the European Union and in particular human dignity, the integrity of the person, the protection of personal data, the freedom of art and science and to conduct business, non-discrimination, the right to health protection and access to health care, and the rights of the child. To achieve these aims, all supervisory and SoHO activities should always be carried out in a manner that fully respects those rights and principles. The right for dignity and integrity of donors, recipients and of offspring born from medically assisted reproduction should always be taken into account, amongst others, by ensuring that consent for donation is freely given and donors or their representatives are informed with regards to the intended use of the donated material, that donor eligibility criteria are based on scientific evidence and criteria of compatibility between donors and recipients, that the use of SoHOs in humans is not promoted for commercial purposes or with false or misleading information regarding efficacy so that the donors and recipients can make well-informed and deliberate choices, that activities are conducted in a transparent manner that prioritises the safety of donors and recipients, and that allocation and equitable access to SoHOs are defined in a
Amendment 294 #
Proposal for a regulation Recital 44 (44) This Regulation respects the fundamental rights and observes the principles recognised in particular by the Charter of Fundamental Rights of the European Union and in particular human dignity, the integrity of the person, the protection of personal data, the freedom of art and science and to conduct business, non-discrimination, the right to health protection and access to health care, and the rights of the child. To achieve these aims, all supervisory and SoHO activities should always be carried out in a manner that fully respects those rights and principles. The right for dignity and integrity of donors, recipients and of |